Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Retained Earnings (2016 - 2025)

Iovance Biotherapeutics has reported Retained Earnings over the past 13 years, most recently at -$2.8 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$2.8 billion for Q4 2025, down 265247.04% from a year ago — trailing twelve months through Dec 2025 was -$2.8 billion (down 265247.04% YoY), and the annual figure for FY2025 was -$2.8 billion, down 265247.04%.
  • Retained Earnings for Q4 2025 was -$2.8 billion at Iovance Biotherapeutics, down from $16.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for IOVA hit a ceiling of $16.1 million in Q3 2025 and a floor of -$2.8 billion in Q4 2025.
  • Median Retained Earnings over the past 3 years was -$891.6 million (2023), compared with a mean of -$1.2 billion.
  • Biggest five-year swings in Retained Earnings: skyrocketed 192.06% in 2024 and later plummeted 2155888.79% in 2025.
  • Iovance Biotherapeutics' Retained Earnings stood at $2.5 million in 2023, then tumbled by 141.41% to -$1.0 million in 2024, then crashed by 265247.04% to -$2.8 billion in 2025.
  • The last three reported values for Retained Earnings were -$2.8 billion (Q4 2025), $16.1 million (Q3 2025), and -$2.6 billion (Q2 2025) per Business Quant data.